These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37497426)

  • 21. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
    Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
    J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
    Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
    Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
    Tao J; Bukanova EN; Akhtar S
    J Intensive Care; 2018; 6():34. PubMed ID: 29942519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma.
    Wienhold J; Rayatdoost F; Schöchl H; Grottke O
    Curr Opin Anaesthesiol; 2024 Apr; 37(2):101-109. PubMed ID: 38390922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding.
    Brown CS; Mattson AE; Cabrera D; Coelho-Prabhu N; Rabinstein AA; Dettling T; McBane RD; Bellolio F
    Am J Emerg Med; 2023 Nov; 73():1-6. PubMed ID: 37562071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
    Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
    J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
    Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
    Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 33. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
    Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
    Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.
    Kimpton M; Siegal DM
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):204-208. PubMed ID: 31808849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
    Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
    J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis.
    Shrestha DB; Budhathoki P; Adhikari A; Shrestha S; Khati N; Mir WAY; Joshi T; Shrestha A
    Cureus; 2021 Dec; 13(12):e20632. PubMed ID: 35103198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Periprocedural and Early Pericardial Effusions With Tamponade Following Ablation of Atrial Fibrillation With Uninterrupted Factor Xa Inhibitors: A Case Series.
    Gianni C; DI Biase L; Mohanty S; Trivedi C; Bai R; Al-Ahmad A; Burkhardt JD; Gallinghouse GJ; Horton RP; Sanchez JE; Hranitzky PM; Lakkireddy D; Mansour MC; Santangeli P; Zado ES; Marchlinski FE; Beheiry S; Hao SC; Couts L; Gibson D; Natale A
    J Cardiovasc Electrophysiol; 2016 Apr; 27(4):399-403. PubMed ID: 26756289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.